Key facts
- This page summarizes David E. Wheadon's Form 4 filing for Vaxart, Inc. (VXRT).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 17 Jun 2021, 19:29.
David E. Wheadon - 16 Jun 2021 Form 4 Insider Report for Vaxart, Inc. (VXRT)
- Form type
- 4
- Accepted by SEC
- 17 Jun 2021, 19:29:43 UTC
- Previous filing
- 01 Jun 2021
- Next filing
- 31 May 2022
- SEC filing
- View on sec.gov
- Reporting owner signature
- /s/ Margaret Echerd, Attorney-in-Fact for David Wheadon
Source evidence
5 source fields
Reporting owner
1 detail
Key filing fact
David E. Wheadon filed Form 4 for Vaxart, Inc. (VXRT) on 17 Jun 2021.
Change
- Previous filing in this sequence was filed on 01 Jun 2021.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
See Original Filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
VXRT
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +65,700
- Change %
- Price
- $0.000000
- Shares after
- 65,700
- Date
- 16 Jun 2021
- Ownership
- Direct
- Underlying class
- Common stock
- Underlying amount
- 65,700
- Exercise price
- $6.54
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The option was granted by the board of directors of Vaxart, Inc. effective on May 10, 2021, subject to stockholder approval of an amendment to the Vaxart, Inc. 2019 Equity Incentive Plan, under which the stock option was granted. Vaxart, Inc.'s stockholders approved the plan amendment on June 16, 2021.
Footnote F2
The shares subject to this option shall vest annually over three years from the vesting commencement date of April 21, 2021, the date of the grantee's appointment as a director of Vaxart, Inc.